Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Common Equity (2018 - 2025)

BioNexus Gene Lab's Common Equity history spans 8 years, with the latest figure at $8.6 million for Q4 2025.

  • Quarterly results put Common Equity at $8.6 million for Q4 2025, up 3.51% from a year ago — trailing twelve months through Dec 2025 was $8.6 million (up 3.51% YoY), and the annual figure for FY2025 was $8.6 million, up 3.51%.
  • Common Equity for Q4 2025 was $8.6 million at BioNexus Gene Lab, up from $6.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $9.7 million in Q4 2023 to a low of $5.6 million in Q2 2023.
  • The 5-year median for Common Equity is $7.2 million (2021), against an average of $7.6 million.
  • The sharpest move saw Common Equity soared 70.7% in 2024, then dropped 27.4% in 2025.
  • Year by year, Common Equity stood at $7.2 million in 2021, then fell by 7.17% to $6.7 million in 2022, then soared by 44.9% to $9.7 million in 2023, then decreased by 13.82% to $8.3 million in 2024, then increased by 3.51% to $8.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $8.6 million, $6.8 million, and $7.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.